The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.
Suayib Yalcin
No relevant relationships to disclose
Suleyman Buyukberber
No relevant relationships to disclose
Ugur Yilmaz
Honoraria - Honoria for specific speeches and advisory board meetings
Research Funding - Grants for participating to multicenter trials
Po-Huang Lee
No relevant relationships to disclose
Vichien Srimuninnimit
No relevant relationships to disclose
Pin-Wen Lin
No relevant relationships to disclose
Mostafa M. Elserafy
No relevant relationships to disclose
Moustafa Manieh
No relevant relationships to disclose
Patrapim Sunpaweravong
Consultant or Advisory Role - advisory board
Honoraria - Speaker
Other Remuneration - conference attendance
Yuriy Istomin
No relevant relationships to disclose
Virote Sriuranpong
No relevant relationships to disclose
Tsann-Long Hwang
No relevant relationships to disclose